Clinical human trials begin for COVID-19 vaccine in China

[JSCh]

Instead of playing politic and perception distorting propaganda game, protecting the life of Chinese people is more important. China would invest in various technology, such that China would have more options when there is a need for vaccination.

There is another technology for vaccine that is different from mRNA, the DNA vaccine.

Back in January 30, 2020, when Wuhan is in lockdown,

https://www.facebook.com/INOVIOPharmaceuticals/posts/972699013113708

Press release from January 4, 2021,

​

PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.​

​

Under the collaboration and license agreement, Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO with the right to sublicense to INOVIO's manufacturing partners. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO's global INO-4800 regulatory filings and INOVIO will provide its INO-4800 clinical data for Advaccine to incorporate into its marketing applications in Greater China. Advaccine will make to INOVIO an upfront payment of $3.0 million as well as pay an aggregate of $108.0 million upon the achievement of specified development and sales-based milestones for INO-4800 in Greater China. INOVIO will be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China.​

​

....​

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...

www.prnewswire.com

https://twitter.com/x/status/1424725298248028162

INOVIO Pharmaceuticals @InovioPharma

Today we announced that INOVIO and Advaccine received regulatory allowance for two heterologous prime-boost clinical trials in China using INO-4800, INOVIO's #COVID19 DNA vaccine candidate. Read more: https://bit.ly/3saui5R

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

Announcement builds on INOVIO's expanded partnership with Advaccine for INNOVATE, a global efficacy Phase 3 trial for INO-4800 INO-4800's Phase 1 and 2 trial data, combined with recent findings that showed robust T cell level response against the delta variant, position it well for both primary...

ir.inovio.com

9:32 PM · Aug 9, 2021

 

[JSCh]

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations
2021-08-10

• CoronaVac® generates good immune memory after second dose
• Third dose of vaccine significantly increased neutralizing antibody levels in adults and elderly population
• Findings indicate a third dose of CoronaVac® is well-tolerated in the elderly population
• No serious vaccine-related adverse reactions reported

August 10, 2021 07:00 AM Eastern Daylight Time

BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today the publication of two papers, which are available on Medrxiv. The publications detail findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac® in two- and three-dose schedules. The results indicate that a third booster dose of CoronaVac® induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine. This research provides important scientific data and supplement existing research to help policymakers develop strategies for vaccine rollout and timing of booster doses.

....

--> http://www.sinovac.com.cn/news/shownews.php?id=1286&lang=en

 

[JSCh]

https://twitter.com/x/status/1426741756788318211

 

[JSCh]

https://twitter.com/x/status/1427878357731975169

Global Times @globaltimesnews
China state-affiliated media

A #COVID19 #vaccine developed & produced by #Sinopharm's institute in Wuhan has been approved for emergency use on people aged 3-17 by Chinese national authority.


2:21 PM · Aug 18, 2021

 

[JSCh]

China Zhifei's COVID shot largely retains effect against Delta variant-lab study

A COVID-19 vaccine developed by a unit of China's Chongqing Zhifei Biological Products (300122.SZ) largely retained its neutralising effect against the Delta variant but there was a slight reduction, Chinese researchers found in a laboratory study.

www.reuters.com

The pre-print paper refer above is now published.

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants - The Lancet Microbe

 

[JSCh]

https://twitter.com/x/status/1429624433149239302

 

[JSCh]

https://twitter.com/x/status/1429781436714819595

Global Times @globaltimesnews
China state-affiliated media

Bahrain announced on August 17 the approval of China's #Sinopharm #COVID-19 vaccine for children aged 3-11 with complications and weakened immune systems. Meanwhile, the health ministry also approved giving the Sinopharm vaccine to children aged 12-17.

8:23 PM · Aug 23, 2021

 

[JSCh]

Study shows inhalable nanocatchers can protect lung cells against SARS-CoV-2

Inhalable nanocatchers that contain hACE2 have been recently developed by a group of researchers, providing a plethora of potential benefits in comparison to existing treatments against COVID-19.

www.news-medical.net

 

[JSCh]

https://twitter.com/x/status/1431471646011842560

Shen Shiwei沈诗伟 @shen_shiwei Aug 28, 2021
China state-affiliated media

Nepali cabinet meeting on Thur. approved Phase III clinical trials of Chinese developed #mRNA vaccine, Dr. Pradip Gyanwali, executive chief of the Health Research Council adds that #Nepal finds out the #vaccine candidate good in terms of safety and efficacy.

 

[JSCh]

Chinese three-shot vaccine nearly 82 per cent effective, says maker

Chongqing Zhifei Biological Products says in an exchange filing that the product has a near-78 per cent efficacy rate against the Delta variant.

www.scmp.com

https://twitter.com/x/status/1431477641085800455

 

[JSCh]

https://twitter.com/x/status/1414544699520557058

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against COVID-19, “CoronaVac”.

www.gavi.org

https://twitter.com/x/status/1431877801049681925

Global Times @globaltimesnews
China state-affiliated media

567,600 doses of Chinese company #Sinovac's COVID-19 #vaccines departed on Sunday morning and are expected to arrive in Algeria’s capital Algiers on Monday. It is the first batch of Sinovac shots delivered through #COVAX.

3:14 PM · Aug 29, 2021

 

[JSCh]

https://twitter.com/x/status/1413562366890061828

Reuters Health @Reuters_Health

A potential COVID-19 vaccine developed by a subsidiary of China's Livzon Pharmaceutical Group Inc (http://000513.SZ) appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.

https://twitter.com/x/status/1432138628558327809

 

[JSCh]

https://twitter.com/x/status/1353925129416421376

China News 中国新闻网 @Echinanews
China state-affiliated media

Hong Kong on Monday authorized Fosun Pharma/BioNTech #COVID19 vacancies for the emergency use. The first batch of 1 million doses are being tested for its safety and quality and will likely be shipped from Germany to Hong Kong late next month.



12:38 PM · Jan 26, 2021

https://twitter.com/x/status/1433240761772830724

China News 中国新闻网 @Echinanews
China state-affiliated media

The first batch of #COVID19 mRNA vaccines provided by the Shanghai-based Fosun Pharma to Taiwan arrived in Taipei on Thursday morning. A total of 932,000 doses of the vaccines were dispatched from Luxembourg Airport on Wednesday afternoon, said the company.


9:30 AM · Sep 2, 2021

 

[JSCh]

Sinopharm subsidiary ready to deliver new COVID-19 drug based on recovered patients' plasma into clinical trials, vital for critical patients' treatment
By Leng Shumei
Published: Sep 04, 2021 12:22 PM

Sinopharm Photo:VCG​

Chinese vaccine producer China National Biotec Group (CNBG), a Sinopharm subsidiary, announced that it has obtained approval of clinical trials for a COVID-19 drug based on human immuneglobulin developed from plasma of recovered COVID-19 patients, which experts said will be effective to treat critical patients.

The drug was unveiled at the 2021 China International Fair for Trade in Services (CIFTIS). CNBG said in a Friday announcement that it obtained approval of clinical trials on August 30.

In addition to the new drug, the CNBG also displayed other six anti-epidemic products, including two updated vaccines effective to combat mutations and another COVID-19 drug based on a monoclonal antibody.

The new drug contains high level of neutralizing antibodies to the novel coronavirus, according to the CNBG.

CNBG has been producing plasma products made of donated plasma from recovered patients since early 2020 and they were believed to be the most effective treatment on COVID-19 patients in severe conditions.

Chinese experts also took these products with them to treat local patients when they went to support foreign countries such as Italy.

The action principle of the newly unveiled drug is similar to previous plasma products. It uses antibodies to neutralize the virus, but would be more effective than the previous products, a Beijing-based immunologist told the Global Times on Saturday.

But it is uncertain how long the clinical trials will take as there are not so many patients in China now, the expert said on condition of anonymity.

The CNBG has not revealed where and when they would launch the clinical trials on the drug.

The expert noted that the drug should be limited to critical patients, as it may cost a lot, but would still be cheaper than monoclonal antibody drugs. He also warned that the drug may contain risks of infection of other viruses, such as HBV and HIV as well as other blood-borne communicated diseases.

The CNBG previously said that it has followed strict screenings to process the donated plasma.

Apart from routine tests, nearly 30 additional items will also be tested, including some common respiratory and intestinal bacteria as well as a pathogen to five kinds of infectious diseases like HIV, HBV, and syphilis. Virus inactivation treatment will also be conducted to improve safety of the plasma products.

According to the CNBG, it took at least a week from collecting plasma to preparing the products that can be used on COVID-19 patients. On average, one recovered patient can donate 400 milliliters of plasma to save two or three patients in critical conditions.

Sinopharm subsidiary ready to deliver new COVID-19 drug based on recovered patients' plasma into clinical trials, vital for critical patients' treatment - Global Times

www.globaltimes.cn

 

[JSCh]

https://twitter.com/x/status/1434691683480834053

People's Daily, China @PDChina
China state-affiliated media

A third dose of #Sinovac vaccine increases the potency, scale, and duration of anamnestic responses against SARS-CoV-2, according to the lab study data published in a preprint paper on medRxiv after researchers analyzed 171 complex structures of SARS-CoV-2 neutralizing antibodies


9:35 AM · Sep 6, 2021